肺
鼻腔给药
炎症
免疫系统
免疫学
医学
药物输送
淫羊藿苷
纳米载体
药理学
化学
药品
病理
内科学
替代医学
有机化学
作者
Haijun Gong,Jinhu Chen,Jing Zhang,Hui Wang,Xiuzhen Mei,Pei Yu,Yanna Wei,Beibei Liu,Yuzi Wu,Lifang Yang,Zhenzhen Zhang,Zhixin Feng,Chao Zhang
摘要
The increasing antibiotic resistance of mycoplasma underscores the need for new therapeutic strategies, particularly those targeting alveolar macrophages (AMs). AMs are crucial for pulmonary immunity but suffer from impaired immune and endocytic functions during mycoplasma infection due to TNF-α-induced necroptosis. This study demonstrates that icariin (ICA), a bioactive flavonoid with anti-inflammatory properties, reduces necroptosis and TNF-α secretion in infected AMs, mitigating lung inflammation. However, the poor water solubility and the pulmonary surfactant's mucus layer limit its effective delivery. To address these challenges, we developed a novel pulmonary infection-adapted artificial cell-derived vesicles (PIA-ACDVs). PIA-ACDVs-ICA, made with DPPC based liposome loading with ICA and fused with Annexin A1-overexpressing macrophage membranes forming ACDVs, showed enhanced uptake by damaged AMs in vitro and in vivo. PIA-ACDVs-ICA demonstrated superior mucosal penetration and macrophage targeting compared to conventional liposomes. In a mouse model of pneumonia induced by mycoplasma, intranasal PIA-ACDVs-ICA significantly reduced bacterial load and lung inflammation, outperforming both oral and conventional nasal icariin delivery methods. The reduction in lung bacterial load and pro-inflammatory macrophages highlights the system's enhanced therapeutic efficacy. These findings suggest that PIA-ACDVs-ICA offers a promising alternative to traditional antibiotics by restoring AMs function. This biomimetic nanocarrier system represents a versatile platform for respiratory infection treatment and may help address antibiotic resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI